Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Nitric Oxide-Releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis through Antimicrobial and Anti-Inflammatory Activity.
Guttman-Yassky E, Gallo RL, Pavel AB, Nakatsuji T, Li R, Zhang N, Messersmith E, Maeda-Chubachi T. Guttman-Yassky E, et al. Among authors: pavel ab. J Invest Dermatol. 2020 Dec;140(12):2531-2535.e2. doi: 10.1016/j.jid.2020.04.013. Epub 2020 May 16. J Invest Dermatol. 2020. PMID: 32428543 Free article. No abstract available.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Guttman-Yassky E, et al. Among authors: pavel ab. J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures.
Wen HC, Czarnowicki T, Noda S, Malik K, Pavel AB, Nakajima S, Honda T, Shin JU, Lee H, Chou M, Estrada Y, Zheng X, Xu H, Krueger JG, Lee KH, Kabashima K, Guttman-Yassky E. Wen HC, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2018 Jul;142(1):324-328.e11. doi: 10.1016/j.jaci.2018.02.047. Epub 2018 Apr 11. J Allergy Clin Immunol. 2018. PMID: 29653116 No abstract available.
Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features.
Chan TC, Sanyal RD, Pavel AB, Glickman J, Zheng X, Xu H, Cho YT, Tsai TF, Wen HC, Peng X, Cueto I, Krueger JG, Guttman-Yassky E. Chan TC, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2018 Sep;142(3):1013-1017. doi: 10.1016/j.jaci.2018.06.016. Epub 2018 Jun 28. J Allergy Clin Immunol. 2018. PMID: 29964056 No abstract available.
An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation.
Song T, Pavel AB, Wen HC, Malik K, Estrada Y, Gonzalez J, Hashim PW, Nia JK, Baum D, Kimmel G, Singer GK, Krueger JG, Guttman-Yassky E. Song T, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2018 Nov;142(5):1631-1634.e13. doi: 10.1016/j.jaci.2018.06.029. Epub 2018 Jul 5. J Allergy Clin Immunol. 2018. PMID: 29981808 No abstract available.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E. Brunner PM, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17. J Allergy Clin Immunol. 2019. PMID: 30121291 Clinical Trial.
Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation.
Sanyal RD, Pavel AB, Glickman J, Chan TC, Zheng X, Zhang N, Cueto I, Peng X, Estrada Y, Fuentes-Duculan J, Alexis AF, Krueger JG, Guttman-Yassky E. Sanyal RD, et al. Among authors: pavel ab. Ann Allergy Asthma Immunol. 2019 Jan;122(1):99-110.e6. doi: 10.1016/j.anai.2018.08.024. Epub 2018 Sep 14. Ann Allergy Asthma Immunol. 2019. PMID: 30223113
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E. Mikhaylov D, et al. Arch Dermatol Res. 2019 Jan;311(1):29-36. doi: 10.1007/s00403-018-1876-y. Epub 2018 Nov 11. Arch Dermatol Res. 2019. PMID: 30417279 Clinical Trial.
Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients.
Brunner PM, Israel A, Leonard A, Pavel AB, Kim HJ, Zhang N, Czarnowicki T, Patel K, Murphrey M, Ramsey K, Rangel S, Zebda R, Soundararajan V, Zheng X, Estrada YD, Xu H, Krueger JG, Paller AS, Guttman-Yassky E. Brunner PM, et al. Among authors: pavel ab. Ann Allergy Asthma Immunol. 2019 Mar;122(3):318-330.e3. doi: 10.1016/j.anai.2018.11.025. Epub 2018 Dec 1. Ann Allergy Asthma Immunol. 2019. PMID: 30508584
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K, Wen HC, Xu H, Estrada YD, Peng X, Chen M, Shah N, Suarez-Farinas M, Pavel AB, Nograles K, Guttman-Yassky E. Simpson EL, et al. Among authors: pavel ab. J Invest Dermatol. 2019 May;139(5):1063-1072. doi: 10.1016/j.jid.2018.10.043. Epub 2018 Dec 5. J Invest Dermatol. 2019. PMID: 30528828 Free article. Clinical Trial.
84 results